Atara Biotherapeutics (ATRA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

This past spring, Congress passed a number of important tax provisions that will impact how taxpayers manage their assets and estates. One of particular significance is the American Tax Relief Act of ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Targeted cancer therapies work by blocking a single oncogenic pathway to halt tumor growth. But because cancerous tumors have the unique ability to activate alternative pathways, they are often able ...

Atara Biotherapeutics (ATRA) has been beaten down lately with too much selling pressure. While the stock has lost 33% over the past four weeks, there is light at the end of the tunnel as it is now in ...

) has been revised to $9.52 / share. This is a decrease of 52.54% from the prior estimate of $20.06 dated January 11, 2026. The price target is an average of many targets provided by analysts. The ...

This report should not be treated as legitimate news and instead it should be recognized for what it truly is: a sophisticated public relations campaign designed to manipulate public opinion and ...

Treatment combining ATRA and chemotherapy (CT) has improved the outcome of APL patients, by comparison with CT alone. ATRA syndrome is a life-threatening complication of ATRA treatment whose ...

Atara Biotherapeutics ATRA shares have rallied 82.4% in a month, primarily driven by a positive regulatory update earlier in May on its lead product candidate, tabelecleucel (tab-cel). The update ...